5 Considerations for Upleveling Your Real-World Data and Evidence Strategy

5 Considerations for Upleveling Your Real-World Data and Evidence Strategy

Skip to content

Blog / Healthcare & Life Sciences / From Data to Insights: 5 Considerations for Upleveling Your Real-World Data and Evidence Strategy

Oct 13, 2026 / 8 min read Healthcare & Life Sciences Copy post link Open in Claude Open in ChatGPT

From Data to Insights: 5 Considerations for Upleveling Your Real-World Data and Evidence Strategy

Alistair Hankin +1

For life sciences organizations, real-world data (RWD) has become one of the enterprise’s most valuable assets. Operationalized as real-world evidence (RWE), it can illuminate how therapies perform beyond controlled clinical trials, revealing care gaps, access barriers, adherence challenges, benefit-risk signals, market expansion opportunities and outcomes across broader, more diverse patient populations.

Yet the central challenge isn’t a lack of data. Most organizations have more data than they can effectively use. The more interesting question is whether they can turn that data into trusted, usable context quickly enough to matter. RWD strategies are moving toward a continuously refreshed, agent-ready foundation for evidence generation, decision support and timely action.

Life sciences organizations need evidence strategies that can keep up with pipeline acceleration, more personalized care, rising outcomes expectations and the pressure to launch across complex global markets. That means making evidence generation a more proactive business capability that supports better decisions across development, medical, commercial and market access.

Here are five considerations for upleveling your evidence generation strategies.

1. Design for connected, multimodal data and shared semantic context

A single data source cannot provide a complete view of the patient journey, disease progression, treatment behavior or market dynamics. Claims show utilization patterns, while electronic health record (EHR), lab, imaging, genomics, registry, wearable and patient-generated data add clinical and behavioral depth. Connecting these modalities is necessary, but simply moving everything into one repository isn’t enough, and it often isn’t possible under strict privacy protection regulations. Provenance, definitions, consent, permitted use, lineage, quality, freshness and fitness for purpose must always live with the data. Privacy and data sovereignty should shape how patient data is linked, accessed, shared and used as a nonnegotiable from the beginning.

This requires an enterprise approach to RWD in which different teams can work from trusted, connected views of the patient, disease, treatment and market. The technology matters, but the strategic question comes first: Which decisions should become faster, more repeatable or more patient-centered when these data sources are connected?

That’s a collective responsibility:

Data originators can increase data value through clear provenance, consent, permitted-use boundaries, quality signals and privacy-preserving controls.

Aggregators can move beyond static data sets with refreshed products, common definitions, transparent limitations and evidence-ready context to prove business value.

Enabling technology providers can support privacy-preserving linkage, secure collaboration, policy enforcement and usable applications.

Life sciences organizations can build reusable evidence capabilities instead of assembling disconnected, repetitive extracts for every question.

The goal here is to preserve context while making multimodal data usable and compliant across the evidence lifecycle. It’s the less glamorous, and often more consequential, work of AI transformation: getting definitions, lineage, access policies and data quality pipelines right so the next use case or application doesn’t require starting over.

2. Treat RWE as an ecosystem of collaborative products, not a sequence of projects

RWE has often been treated as a specialized capability owned by R&D, health economics and outcomes research (HEOR), epidemiology, medical or market access teams. Those functions remain essential, but the strategic value of evidence generation now extends across the life sciences value chain and the broader healthcare ecosystem.

R&D, Clinical Ops, Medical Affairs and Commercial teams all rely on RWD, from protocol design and site selection to care-gap analysis and launch planning. As these use cases expand, the unit of value is changing. The future isn’t a collection of one-off studies built from raw files. It’s a portfolio of reusable data and insight products, including:

Longitudinal patient journeys, computable patient states and treatment pathways

Care gaps, outcomes cohorts, safety and benefit-risk signals

Provider, site, payer coverage and access patterns

Trial-like populations and external comparator cohorts

Reusable phenotypes, analysis plans, evidence packages, and insight and reporting applications

This creates opportunity throughout the ecosystem. RWE then truly becomes a team sport: The more reusable and interoperable each participant’s contribution becomes, the faster the ecosystem can answer the next question.

3. Move from episodic to continuous evidence generation

For many organizations, traditional RWD workflows still begin with one-off requests: a study is commissioned, data is assembled, analysis is conducted and findings are reported. This creates an unacceptable lag (often months) between the questions being asked and the evidence available to answer them, given today’s shifting healthcare demands.

The next generation of evidence generation will be maintained as a living capability. Persistent, governed pipelines can refresh as new data slices, populations and modalities become available. Patient-state and trajectory models can organize multimodal events over time, helping teams follow treatment exposure, response, progression, adverse events and outcomes with increasing attribution.

Continuous pipelines make near real-time evidence generation possible, meaning teams can close the gap between a signal in the real world, its validation and the next decision. In practice, that can help teams:

Catch postmarket signals sooner, such as safety risks, care gaps, missed diagnoses and emerging journey patterns

Monitor treatment responses, access hurdles and adherence changes in real time

Adjust trial feasibility, recruitment targets and diversity goals as patient dynamics shift

Match the right...